Zobrazeno 1 - 10
of 16 410
pro vyhledávání: ''
Autor:
Paul Mitchell, G Rivalland, Hui Yu, Fred R. Hirsch, R. Mosher, L Churilov, K Asadi, Christopher J. Rivard, S Heynemann
Publikováno v:
Clinical Lung Cancer. 23:e90-e98
Background NaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumours including breast, thyroid, ovarian and non-sm
Autor:
Sebastian F. Schoppmann, Emmanuella Guenova, Gerd Jomrich, Matthias Preusser, Robin Ristl, Dariga Ramazanova, Aysegül Ilhan-Mutlu, Richard Grose, Christina Fassnacht, Dagmar Kollmann, Yi-Chien Tsai
Publikováno v:
European Journal of Surgical Oncology. 48:383-390
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-
Autor:
Trenton Reinicke, Justin F. Gainor, Marissa N Bruno, Henning Willers, Erika Nakajima, Anand S. Dighe, Yi-Bin Chen, Vivek Naranbhai, Leyre Zubiri, Aleigha Lawless, Brittany Y Bertaux, Aditya Bardia, Kerry L. Reynolds, Rebecca R. Saff, Jocelyn R. Farmer, Kerri St. Denis, A. John Iafrate, Elizabeth Niehoff, Joan How, Mustafa Sakhi, Grace Kirkpatrick, Arthur Y. Kim, Wilfredo-Garcia Beltran, Alejandro B. Balazs, Alexander Gavralidis, Caroline Barabell, Monica A Jackson, C. Bowes, Lailoo A Perriello, Amir T. Fathi, Andrew M. Brunner, Evan C. Lam, Gabriela S. Hobbs, Grace Hambelton, Christian N Nambu, Kimberly G. Blumenthal, Julia Thierauf, Laura Spring, Elyssa Denault, Claire A. Pernat, Steven J. Isakoff, Ryan J. Sullivan, Cristhian J Berrios-Mairena, Jennifer L Peterson, Lindsey Mortensen, Onosereme Ofoman
Publikováno v:
Journal of Clinical Oncology. 40:12-23
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood. METHODS We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti–SARS-CoV-2 immuno
Autor:
Renu Dhanasekaran, Chen Wang, Jun Yin, Lewis R. Roberts, Zongming Eric Chen, Saba Yasir, Chantal E. McCabe, Keun Soo Ahn, Michael Torbenson, Nguyen H Tran, Tiffany M Bainter, Daniel R. O'Brien
Publikováno v:
Hum Pathol
Beta-catenin (CTNNB1) is commonly mutated in hepatocellular carcinoma (HCC). CTNNB1-mutated HCC has important clinical correlates, such as being immune cold and less likely to respond to immune checkpoint inhibitor therapies. It remains unclear, howe
Publikováno v:
Human Pathology. 119:51-58
Oncogenic mutations in the adenomatous polyposis coli (APC)/Wnt signaling pathway are well documented. The FBXW7 gene (F-box and WD repeat domain-containing 7) encodes a member of the ubiquitin-proteasome complex that is more recently described to an
Autor:
Hiroyuki Motoyama, Norifumi Kawada, Kohei Kotani, Akihiro Tamori, Naoshi Odagiri, Hideki Fujii, Hoang Hai, Le Thi Thanh Thuy, Atsushi Hagihara, Minh Phuong Dong, Masaru Enomoto, Ritsuzo Kozuka, Etsushi Kawamura, Sawako Uchida-Kobayashi, Kanako Yoshida
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Scientific Reports
Scientific Reports
Soluble immune checkpoint molecules are emerging novel mediators of immune regulation. However, it is unclear whether soluble immune checkpoint proteins affect the development of hepatocellular carcinoma (HCC) during nucleos(t)ide analogue (NA) treat
Autor:
Joanne Xiu, Michael J. Pishvaian, Ari M. Vanderwalde, Jia Zeng, Yasmine Baca, Sunnie S. Kim, John L. Marshall, W. Michael Korn, Anthony F. Shields, Axel Grothey, Heinz-Josef Lenz, Philip A. Philip, Mohamed E. Salem, Jimmy J. Hwang, Richard M. Goldberg, Michael Cerniglia
Publikováno v:
Mol Cancer Ther
The prevalence of homologous recombination–DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adeno
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Griselda Martrat, Jorge García-González, Guillermo Lopez-Vivanco, Santiago Viteri, J. Garde, Manuel Cobo, Miguel Sampayo, Rafael Rosell, Jose Miguel Sanchez, Niki Karachaliou, Ivanna Sullivan, Miguel Angel Molina-Vila, Andrea Malfettone, Margarita Majem
Publikováno v:
European Journal of Cancer. 159:174-181
Aim of the study The AZENT ( NCT02841579 ) study aimed to assess the efficacy and safety of first-line osimertinib in patients with epidermal growth factor receptor(EGFR)mutation–positive advanced non–small-cell lung cancer (NSCLC) and with a coe
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor